Indications and Usage &
Important Safety Information
Important Safety Information
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
To report suspected adverse reactions, contact Harmony Biosciences at 1-800-833-7460 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see accompanying
Full Prescribing Information.
WAKIX Is Included in the AASM Clinical Practice Guideline*
Strong recommendation for adults
with narcolepsy; clinically significant
improvement in EDS and cataplexy
WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation and in patients with severe hepatic impairment.
AASM, American Academy of Sleep Medicine. | |
* | Clinical practice guideline on the treatment of central disorders of hypersomnolence, published in the Journal of Clinical Sleep Medicine, includes recommendations for treatment of narcolepsy in adults. |
US-WAK-2000172/Sep 2021
Copay Program
Eligible patients may pay as little as a
$0 copay on their WAKIX prescription*
* | This offer is valid only for patients with commercial (nongovernment-funded) insurance. Additional terms and conditions apply. |
US-WAK-2100082/May 2021